PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsFirst gene therapy for leukaemia approved

BioNews

First gene therapy for leukaemia approved

Published 12 September 2017 posted in News and appears in BioNews 916

Author

Meetal Solanki

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The world's first cancer treatment which uses a patient's own genetically modified immune cells has been approved...

The world's first cancer treatment which uses a patient's own genetically modified immune cells has been approved.

The treatment, called Kymriah (tisagenlecleucel), is also the first gene therapy to be approved in the USA by the Food and Drug Administration (FDA).

'We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer,' said FDA commissioner Dr Scott Gottlieb. 'New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.'

The drug is a treatment for acute lymphoblastic leukaemia (ALL), a type of cancer which causes the bone marrow to produce abnormal B or T lymphocytes (white blood cells). The National Cancer Institute estimates that approximately 3,100 patients aged 20 and younger are diagnosed with ALL each year.

Produced by Novartis, Kymriah is made from the patient's own T lymphocytes, which are filtered from the patient's blood and then genetically modified to include a gene coding for a protein called chimeric antigen receptor (CAR). The so-called CAR-T cells are then injected back in the patient, where they are able to recognise and destroy leukaemic B cells.

Kymriah has an advantage over traditional chemotherapy as it does not attack the patient's healthy cells and weaken the body's natural defences. Clinical trials with 63 paediatric and young adult patients with relapsed ALL showed an 83 percent overall remission rate within three months of treatment.

Subsequently, the FDA has approved Kymriah for ALL patients over 25 who have relapsed or have not responded to other treatments.

'Not only does Kymriah provide [patients] with a new treatment option where very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials,' said Dr Peter Marks, director of the FDA's Centre for Biologics Evaluation and Research.

However the drug does have potentially life-threatening side effects, including inflammation and destruction of normal B cells which leaves patients prone to infections. The FDA requires hospitals that dispense Kymriah be specially certified to treat such side effects.

Although delivered as a one-time dose, Kymriah is priced at US $475,000. Dr Craig Devoe of Northwell Health Cancer Institute, New York, told AFP that he did not think the price was reasonable, and questioned how long treatment would be effective. 'Not just responding but staying in response long term is what patients want,' he said. 'We really don't know how long these cells are going to stay active.'

An application with the European Medicines Agency is expected to be filed by the end of the year, and the FDA may also approve Kymriah to treat lymphoma.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
4 February 2022 • 2 minutes read

Leukaemia patients still in remission a decade after CAR-T gene therapy

by Farah Alam

Two patients who received CAR-T gene therapy over a decade ago are still in remission, the longest follow-up study of its kind has shown...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 August 2018 • 2 minutes read

Special rules for US gene therapy trials relaxed

by Rikita Patel

US gene therapy trials will now be treated like other clinical trials, as the National Institutes for Health step back from regulating them...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 October 2017 • 2 minutes read

FDA approves second gene therapy for cancer

by Jen Willows

The US Food and Drug Administration have approved the world’s second gene therapy to target blood cancer...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 September 2017 • 2 minutes read

Gene therapy reverses multiple sclerosis in mice

by Sarah Gregory

A novel gene therapy can reverse the symptoms and progression of disease in a mouse model of multiple sclerosis...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 September 2017 • 2 minutes read

Gene therapy for cancer halted after patient death

by Ebtehal Moussa

Two trials assessing gene therapy for blood cancer have been put on hold by the US Food and Drug Administration, following a patient fatality...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
24 July 2017 • 2 minutes read

Gene therapy for leukaemia set for FDA go-ahead

by Dr Loredana Guglielmi

A drug for leukaemia that genetically alters patients' own cells to fight cancer, has cleared a critical hurdle in gaining commercial approval...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
9 May 2017 • 2 minutes read

Stem cell test could improve leukaemia treatment

by Dr Loredana Guglielmi

Researchers have developed a stem cell test that could rapidly predict how patients with acute myeloid leukaemia will respond to treatment...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 May 2017 • 2 minutes read

Genome editing successfully treats leukaemia

by Dr Loredana Guglielmi

Doctors at London's Great Ormond Street Hospital have used genome editing to successfully treat two children with leukaemia...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
18 February 2016 • 2 minutes read

T-cell therapy leads to 'dramatic remission' of blood cancers

by Julianna Photopoulos

Trials using genetically engineered immune cells have shown 'extraordinary results' in treating blood cancers in terminally ill patients, say researchers...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 February 2014 • 2 minutes read

T-cell gene therapy successful in early clinical trial

by Chris Hardy

Researchers trialling a gene therapy-based treatment for leukemia have said the early results go beyond anything they could have thought of in their 'wildest dreams'...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Actor Sofia Vergara frozen embryo lawsuit dismissed

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

15 August 2022 • 2 minutes read

Call to end ban on HIV-positive partner gamete 'donation'

15 August 2022 • 2 minutes read

Melanoma invades new tissues using nerve cell gene

15 August 2022 • 2 minutes read

Exceeding alcohol limits could damage DNA and accelerate ageing

15 August 2022 • 2 minutes read

Blood cell gene mutations affect mitochondria, increasing cardiovascular disease risk

15 August 2022 • 2 minutes read

Jumping gene helps immune system fight viruses

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856